BioCryst Pharmaceuticals 2025 Q3 Earnings Record Net Income Surges 191.9%

Generated by AI AgentDaily EarningsReviewed byDavid Feng
Wednesday, Nov 5, 2025 7:19 am ET1min read
Aime RobotAime Summary

- BioCryst's Q3 2025 net income surged 191.9% to $12.9M, driven by 36.1% revenue growth to $159.4M.

- The company raised ORLADEYO revenue guidance to $590–$600M and cut non-GAAP operating expenses to $430–$440M.

- BioCryst acquired

Astria Therapeutics
for $13/share and appointed Ron Dullinger as CCO, signaling expansion plans.

- Stock rose 0.9% post-earnings but fell 6.63% weekly, reflecting mixed analyst reactions and market skepticism.

BioCryst Pharmaceuticals (BCRX) reported Q3 2025 earnings that exceeded expectations, with a record net income of $12.9 million and a 36.1% revenue increase. The company raised its full-year ORLADEYO revenue guidance to $590–$600 million while lowering non-GAAP operating expenses.

Revenue

Driven by robust demand for its flagship product ORLADEYO, BioCryst’s total revenue surged to $159.40 million in Q3 2025, up 36.1% year-over-year. Product sales, net, accounted for $157.74 million, with collaborative and other revenues contributing $1.66 million. The growth was primarily fueled by strong patient retention and new prescriptions for ORLADEYO, despite competition from new prophylactic therapies.


Earnings/Net Income

BioCryst returned to profitability with Q3 2025 net income of $12.9 million, reversing a $14.03 million loss in Q3 2024. The company achieved a record high net income, marking a 191.9% positive swing. Non-GAAP net income reached $35.6 million, or $0.17 per share, reflecting a 1012% increase year-over-year. This turnaround underscores the company’s strong operating leverage and effective cost management.


Post-Earnings Price Action Review

Following the earnings report, BioCryst’s stock price edged up 0.90% on the latest trading day but declined 6.63% over the subsequent full trading week and 5.45% month-to-date. Analysts had mixed reactions, with some upgrading their ratings to “buy” or “overweight” while others lowered price targets. The stock’s volatility highlights market skepticism despite improved financial performance.


CEO Commentary

CEO Jon Stonehouse emphasized the company’s momentum in Q3, citing ORLADEYO’s 37% year-over-year revenue growth and the successful sale of the European business. He highlighted strategic moves, including the acquisition of Astria Therapeutics, as pivotal for long-term growth. The leadership tone was optimistic, with Stonehouse expressing confidence in the team’s ability to drive innovation and profitability.


Guidance

BioCryst raised its FY 2025 ORLADEYO revenue guidance to $590–$600 million and lowered non-GAAP operating expenses to $430–$440 million. The company remains on track for net income and positive cash flow for the full year, excluding the impact of debt prepayments and the European business sale.


Additional News

BioCryst announced a definitive agreement to acquire Astria Therapeutics for $13 per share, expected to close in Q1 2026. The deal adds navenibart, a Phase 3 HAE candidate, to its portfolio. Additionally, Ron Dullinger was appointed as Chief Commercial Officer, effective January 1, 2026, bringing decades of commercial leadership experience. Insider activity included Director Theresa Heggie selling 70,000 shares for $595,700, reducing her holdings by 51.72%.


<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-qwen_generated_1762345085245.jpg.png" style="max-width:100%;">

Comments



Add a public comment...
No comments

No comments yet